KFO
VRDN icon

Kopp Family Office’s Viridian Therapeutics VRDN Stock Holding History

Kopp Family Office’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-55,295
Closed -$1.08M – 30
2026
Q1 		$1.08M Sell
55,295
-117,878
-68% -$3.5M 0.74% 16
2025
Q4 		$5.39M Sell
173,173
-20,657
-11% -$567K 3.44% 9
2025
Q3 		$4.18M Sell
193,830
-9,400
-5% -$170K 2.72% 14
2025
Q2 		$2.84M Sell
203,230
-2,177
-1% -$29.5K 1.84% 18
2025
Q1 		$2.77M Hold
205,407
– – 1.91% 16
2024
Q4 		$3.94M Sell
205,407
-330
-0.2% -$7.17K 2.5% 12
2024
Q3 		$4.68M Hold
205,737
– – 2.98% 13
2024
Q2 		$2.68M Buy
205,737
+97
+0% +$1.34K 1.66% 12
2024
Q1 		$3.6M Buy
205,640
+40
+0% +$775 2.06% 12
2023
Q4 		$4.48M Sell
205,600
-8,690
-4% -$137K 2.62% 12
2023
Q3 		$3.29M Hold
214,290
– – 2.08% 12
2023
Q2 		$5.1M Buy
214,290
+83,002
+63% +$2.13M 2.74% 12
2023
Q1 		$3.34M Buy
131,288
+66,900
+104% +$2.15M 1.8% 12
2022
Q4 		$1.88M Buy
+64,388
New +$1.48M 1.13% 11

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Kopp Family Office's VRDN Position: Q2 2026 in Review

Kopp Family Office sold out of Viridian Therapeutics (VRDN) in Q2 2026, closing a stake of 55,295 shares — an estimated $1.08M sold.

Kopp Family Office first reported a position in VRDN in Q4 2022 and held it in 14 quarters. The position peaked at $5.39M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Kopp Family Office reported no remaining Viridian Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Kopp Family Office sold 55,295 Viridian Therapeutics shares in Q2 2026, an estimated $1.08M.
  • Kopp Family Office first reported a position in Viridian Therapeutics in Q4 2022 and held it in 14 quarters.
  • Kopp Family Office's Viridian Therapeutics position peaked at $5.39M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Kopp Family Office's 13F filing for Q2 2026, filed 9 Jul 2026.